EP3384049
AÐFERÐIR VIÐ AÐ TENGJA ERFÐATILBRIGÐI KLÍNÍSKUM NIÐURSTÖÐUM HJÁ SJÚKLINGUM SEM ÞJÁST AF ALDURSTENGDRI SJÓNDEPILSHRÖRNUN SEM MEÐHÖNDLUÐ ER MEÐ AND-VEGF
:
EP einkaleyfi í gildi á Íslandi:
1.12.2016:
2.8.2023:
16823372.4
:
12.9.2023:
15.11.2023
:
30.11.2036:
30.11.2025:
30.12.2025
:
METHODS OF ASSOCIATING GENETIC VARIANTS WITH A CLINICAL OUTCOME IN PATIENTS SUFFERING FROM AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTI-VEGF
1.12.2016
2.8.2023
12.9.2023
15.11.2023
30.11.2025
:
Regeneron Pharmaceuticals, Inc.:
777 Old Saw Mill River Road, Tarrytown, NY 10591, US
:
PERLEE, Lorah:
Tarrytown, NY 10591, US
:
HAMON, Sara:
Tarrytown, NY 10591, US
:
PAULDING, Charles:
Tarrytown, NY 10591, US
:
Tego IP ehf.:
Pósthólf 8129, 128, Reykjavík,
:
201562262589 P:
3.12.2015:
US
:
201662291274 P:
4.2.2016:
US
:
US2016064403:
1.12.2016
:
C12Q 1/6883
: 8
: 29.11.2023
: 30.11.2024
: Árnason Faktor ehf.
: 9
: 21.11.2024
: 30.11.2025
: Árnason Faktor ehf.